Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

Hartmut Goldschmidt, Meletios A. Dimopoulos, S. Vincent Rajkumar, Katja C. Weisel, Philippe Moreau, Wee Joo Chng, Gábor Mikala, Michele Cavo, Karthik Ramasamy, Kaveri Suryanarayan, Zhaoyang Teng, Richard Labotka, Maria Victoria Mateos

Research output: Contribution to journalArticle

Abstract

In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Goldschmidt, H., Dimopoulos, M. A., Rajkumar, S. V., Weisel, K. C., Moreau, P., Chng, W. J., Mikala, G., Cavo, M., Ramasamy, K., Suryanarayan, K., Teng, Z., Labotka, R., & Mateos, M. V. (Accepted/In press). Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-020-0819-8